FDA Approves Tafinlar Plus Mekinist for Patients With BRAF V600-Mutant Solid Cancers
June 23, 2022 10:56 amby Brielle Benyon
Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.
The Food and Drug Administration (FDA) approved Tafinlar